Literature DB >> 2404747

Thyrotropin potentiation of insulin-like growth factor-I dependent deoxribonucleic acid synthesis in FRTL-5 cells: mediation by an autocrine amplification factor(s).

S Takahashi1, M Conti, J J Van Wyk.   

Abstract

Studies were undertaken to determine the mechanism(s) by which TSH and insulin-like growth factors (IGFs) act synergistically to stimulate DNA synthesis in FRTL-5 cells. As observed in previous studies, the response of these cells to a combination of TSH plus IGFs (or micromolar concentrations of insulin) greatly surpass the sum of the effects of the individual hormones when acting alone. Part of this synergism was eliminated when media containing TSH and IGF-I were replaced every 4 h with fresh media. This suggested that part of the synergism between TSH and IGF-I on cell proliferation is mediated by an amplification factor(s) (AF) released from FRTL-5 cells during incubation. The AF was not specific for thyroid cells, however, since conditioned medium from TSH treated FRTL-5 cells was also found to potentiate the mitogenic effect of IGF-I in the human fibroblast cell line GM3652. It is unlikely that the AF activity secreted by these cells in response to TSH is either IGF or an IGF-binding protein, since the anti-IGF monoclonal antibody sm 1.2 did not attenuate the synergism between TSH and high concentrations of insulin on thymidine incorporation. Analysis of thymidine incorporation into DNA at different times after different patterns of exposure to TSH, IGF-I, or TSH plus IGF-I suggested that at least part of the synergism between the two hormones resulted from increasing the number of quiescent cells recruited into the cell cycle. These results suggested that the TSH-dependent AF might be acting as a competence factor. In a preliminary screen of candidate growth factors, only fibroblast growth factor (FGF) simulated the effect of AF, and its effect was smaller than that obtained with TSH-treated FRTL-5 cells. After preincubation with TSH, FRTL-5 cells exhibited greatly increased responsivity to the mitogenic effects of IGF-I that was manifested by both increased sensitivity to IGF-I, as judged by a decreased EC50, and an increase in their maximum response. TSH pretreatment, likewise, amplified subsequent DNA synthesis in response to serum and tetradecanoyl phorbol acetate. Thus, the mitogenic effect of TSH in FRTL-5 cells is due not only its stimulation of IGF production, but also to its stimulation of one or more AF that greatly enhance the responsivity of these cells to mitogenic stimuli.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2404747     DOI: 10.1210/endo-126-2-736

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  19 in total

1.  Effects of depot growth hormone replacement on thyroid function and volume in adults with congenital isolated growth hormone deficiency.

Authors:  N T F Leite; R Salvatori; M R S Alcântara; P R S Alcântara; C R P Oliveira; J L M Oliveira; F D Anjos-Andrade; M I T Farias; C T F Britto; L M A Nóbrega; A C Nascimento; É O Alves; R M C Pereira; V C Campos; M Menezes; C E Martinelli; M H Aguiar-Oliveira
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

2.  Interaction between cAMP-dependent and insulin-dependent signal pathways in tyrosine phosphorylation in primary cultures of rat hepatocytes.

Authors:  Y Ito; Y Uchijima; M Ariga; T Seki; A Takenaka; F Hakuno; S I Takahashi; T Ariga; T Noguchi
Journal:  Biochem J       Date:  1997-06-01       Impact factor: 3.857

3.  Long-term culture and functional characterization of follicular cells from adult normal human thyroids.

Authors:  F Curcio; F S Ambesi-Impiombato; G Perrella; H G Coon
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

4.  Levothyroxine suppressive therapy for solitary thyroid nodule.

Authors:  E Mainini; I Martinelli; G Morandi; S Villa; I Stefani; C Mazzi
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

Review 5.  Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.

Authors:  Terry J Smith; Laszlo Hegedüs; Raymond S Douglas
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-06       Impact factor: 4.690

6.  Signalling pathways of insulin-like growth factor-I that are augmented by cAMP in FRTL-5 cells.

Authors:  M Ariga; T Nedachi; M Akahori; H Sakamoto; Y Ito; F Hakuno; S Takahashi
Journal:  Biochem J       Date:  2000-06-01       Impact factor: 3.857

7.  Phosphatidylinositol 3-kinase (PI3K) activity bound to insulin-like growth factor-I (IGF-I) receptor, which is continuously sustained by IGF-I stimulation, is required for IGF-I-induced cell proliferation.

Authors:  Toshiaki Fukushima; Yusaku Nakamura; Daisuke Yamanaka; Takashi Shibano; Kazuhiro Chida; Shiro Minami; Tomoichiro Asano; Fumihiko Hakuno; Shin-Ichiro Takahashi
Journal:  J Biol Chem       Date:  2012-07-05       Impact factor: 5.157

8.  Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.

Authors:  Christine C Krieger; Susanne Neumann; Robert F Place; Bernice Marcus-Samuels; Marvin C Gershengorn
Journal:  J Clin Endocrinol Metab       Date:  2014-12-08       Impact factor: 5.958

9.  Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.

Authors:  Seema Kumar; Michael Coenen; Seethalakshmi Iyer; Rebecca S Bahn
Journal:  Thyroid       Date:  2015-08-19       Impact factor: 6.568

10.  Insulin-Like Growth Factor I in Human Thyroid Tissue: Specific Localization by Immunohistochemistry and In Situ Hybridization.

Authors:  Rui M. B. Maciel; Edna T. Kimura; Mirian H. Takahaski; Maria-Honorina C. Lopes; Maria-Isabel S. Mesquita; Alan C. Moses; Vania N. Alberti
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.